Rheumatoid Arthritis
Conditions
Brief summary
Treatment Part 1: The primary efficacy outcome is the proportion of patients in remission at week 24 from baseline according to CDAI. Treatment Part 1: The primary radiographic outcome is the progression of total Sharp van der Heijde score after 48 weeks from baseline. Treatment Part 2: The primary efficacy outcome is the proportion of patients in remission according to CDAI, at the time point 24 weeks after the dose was first reduced.
Interventions
DRUGHYDROXYCHLOROQUINE
DRUGABATACEPT
DRUGAZATHIOPRINE
DRUGSULFASALAZINE
DRUGMETHOTREXATE
DRUGLEFLUNOMIDE
DRUGRoActemra 20 mg/mL concentrate for solution for infusion
DRUGPREDNISOLONE
DRUGTriamcinolone Hexacetonide 20 mg/ml suspension for injection
Sponsors
Karolinska Institutet
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Part 1: The primary efficacy outcome is the proportion of patients in remission at week 24 from baseline according to CDAI. Treatment Part 1: The primary radiographic outcome is the progression of total Sharp van der Heijde score after 48 weeks from baseline. Treatment Part 2: The primary efficacy outcome is the proportion of patients in remission according to CDAI, at the time point 24 weeks after the dose was first reduced. | — |
Countries
Denmark, Iceland, Norway, Sweden
Outcome results
None listed